- GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyoutIn a major stumble for GSK’s $2 billion acquisition of Bellus Health, the UK pharma said Friday it is ending development of camlipixant in refractory chronic cough (RCC) after the drug ...Endpoints · 8d ago↗ source
- Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire→ Silvia Luque announced on LinkedIn that she was named head of US marketing at Zealand Pharma after 13 years in various roles at obesity competitor Eli Lilly. She had been ...Endpoints · 8d ago↗ source
- STAT+: Can ultrasound unlock the power of gene therapy? A startup makes big claimsSonothera is developing a new way to deliver genes into cells that, if borne out, could have a big impact on muscular dystrophy and other diseases.